arrow
T

Takashi Nishimura

Hyogo Medical University
H指数:57
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diagnostic Impact of Two-Dimensional Shear Wave Elastography for Liver Fibrosis: A Multicenter Retrospective Study

二维剪切波弹性成像对肝纤维化的诊断影响:一项多中心回顾性研究

2026-05-010
OAAI
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

不可切除性肝细胞癌接受阿替利珠单抗联合贝伐珠单抗治疗后出血事件的临床特征、预测因素及抗血栓治疗的影响

2026-04-210
PRE
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab

肝内肿瘤负荷对接受阿替利珠单抗联合贝伐珠单抗治疗的合并肝外转移的肝细胞癌患者预后的影响

2026-04-100
PRE
Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab

淋巴细胞-单核细胞比值预测接受度鲁单单抗联合曲美单抗治疗的HCC患者的生存情况

2026-02-260
PRE
Guidance for Liver Rehabilitation in Chronic Liver Disease

慢性肝病肝脏康复指导

2026-01-310
OAAI
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab

基于LDH和CRP的预后评分系统在应用阿替利珠单抗联合贝伐珠单抗治疗的HCC患者中的临床应用价值

2025-09-190
PRE
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis

度鲁特玛联合特瑞普利单抗在合并门静脉血栓和高肿瘤负荷的肝细胞癌患者中的有效性与安全性:一项多中心回顾性分析

2025-09-060
PRE
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma

格瑞特营养风险指数作为不可切除肝癌患者接受度伐利尤单抗联合特瑞普利单抗治疗期间免疫介导不良反应的风险因素的潜在作用

2025-08-200
PRE
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis

达鲁瓦鲁单抗联合特雷美鲁单抗在不可切除肝细胞癌老年患者中的安全性与有效性:一项多中心分析

2025-08-060
PRE
Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study
2025-02-090
PRE
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC
2025-01-220
PRE
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models
2025-01-060
PRE
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice

免疫治疗时代临床实践中durvalumab联合tremelimumab治疗不可切除肝细胞癌的疗效

2024-11-112
OA
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
2024-09-043
PRE